BROAD INSTITUTE | CLINICAL RESEARCH SEQUENCING PLATFORM

CRSP SARS-CoV-2 Real-time Reverse Transcriptase (RT)-PCR Diagnostic Assay

FACILITY NAME: SunnySide Up Nursing Home

Facility code (Broad Use)
NHTI_ssu

PATIENT INFORMATION
(PLEASE PRINT OR AFFIX LABEL - FILL IN ALL FIELDS)

FIRST NAME: JOHN
MIDDLE NAME: S
LAST NAME: SMITH
DATE OF BIRTH (mm/dd/yyyy): 02/04/1974
SEX: M ☑ F ☐ OTHER ☐

SPECIMEN COLLECTION DATE AND TIME (mm/dd/yyyy 00:00 AM/PM)
04/06/2020 1:00 AM/PM

SWAB TUBE BARCODE LABEL

Patient Demographics (Required)

Race:
- ☐ American Indian or Alaska Native
- ☐ Black or African American
- ☐ Native Hawaiian or Pacific Islander
- ☐ Asian
- ☑ White
- ☐ Other

Ethnicity:
- ☐ Hispanic or Latino
- ☑ Non-Hispanic or Latino

REQUESTING PHYSICIAN INFORMATION AND AUTHORIZATION

REQUESTING PHYSICIAN NAME: Michael Mina and Lisa Dobberteen
PHYSICIAN PHONE NO.: (518) 698 2756
REQUESTING PHYSICIAN EMAIL: MJMINA@bwh.harvard.edu
REQUESTING PHYSICIAN SECURE FAX #:
REQUESTING PHYSICIAN NPI #:

TEST ORDERED
SARS-CoV-2 Real-time Reverse Transcriptase (RT)-PCR Diagnostic Assay

Patient is...

- Symptomatic ☐
- Asymptomatic ☑

- Staff ☑
- Resident ☐

I certify that the patient being tested and/or their legal guardian have been informed of the risks, benefits, and limitations of the testing being ordered. I have obtained informed consent, as required by my own state and/or federal laws. I assume responsibilty for returning the results of the testing to the patient and/or their legal guardian and for ensuring that my patient receives appropriate guidance to understand the implications of their test results. Further, I certify that all specimens have been collected, handled, and processed in a manner consistent with those recommended by CRSP.

The CRSP SARS-CoV-2 Real-time Reverse Transcriptase (RT)-PCR Diagnostic Assay is a real-time RT-PCR test intended for the qualitative detection of nucleic acid from the SARS-CoV-2 in nasopharyngeal and oropharyngeal swabs collected from individuals who may have contracted the virus. Testing is limited to the Clinical Research Sequencing Platform at the Broad Institute which is certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA), 42 U.S.C. §263a, to perform high complexity tests.

Negative results do not preclude SARS-CoV-2 infection and should not be used as the sole basis for patient treatment or other patient management decisions. Negative results must be combined with clinical observations, patient history, and epidemiological information.

Clinical Research Sequencing Platform, LLC
320 Charles St
Cambridge, MA 02141
genomics@broadinstitute.org

Laboratory Director: Heidi Rehm, PhD, FACMG
Commonwealth of Massachusetts Clinical Laboratory License 3306
CLIA: 22D2055652 CAP: 8707596

Information for Patients and Providers please visit:
https://covid-19-test-info.broadinstitute.org/#assay-fact-sheets

BROAD INSTITUTE | CLINICAL RESEARCH SEQUENCING PLATFORM

CRSP SARS-CoV-2 Real-time Reverse Transcriptase (RT)-PCR Diagnostic Assay

FACILITY NAME: SunnySide Up Nursing Home

Facility code (Broad Use)
NHTI_ssu

PATIENT INFORMATION
(PLEASE PRINT OR AFFIX LABEL - FILL IN ALL FIELDS)

FIRST NAME: Missy
MIDDLE NAME: E
LAST NAME: Rappaport

DATE OF BIRTH (mm/dd/yyyy): 10/10/1905

SEX: M ☐ F ☑ OTHER ☐

SPECIMEN COLLECTION DATE AND TIME (mm/dd/yyyy 00 00 AM/PM)
01/05/2020 6:00 AM/PM

SWAB TUBE BARCODE LABEL

Patient Demographics (Required)

Race:
- ☐ American Indian or Alaska Native
- ☑ Black or African American
- ☐ Native Hawaiian or Pacific Islander
- ☐ Asian
- ☐ White
- ☐ Other

Ethnicity:
- ☐ Hispanic or Latino
- ☐ Non-Hispanic or Latino

REQUESTING PHYSICIAN INFORMATION AND AUTHORIZATION

REQUESTING PHYSICIAN NAME: Michael Mina and Lisa Dobberteen
PHYSICIAN PHONE NO: (518) 698 2756
REQUESTING PHYSICIAN EMAIL: MJMINA@bwh.harvard.edu
REQUESTING PHYSICIAN SECURE FAX #
REQUESTING PHYSICIAN NPI #

Patient is...
- Symptomatic ☐
- Asymptomatic ☑

- Staff ☐
- Resident ☑

TEST ORDERED
SARS-CoV-2 Real-time Reverse Transcriptase (RT)-PCR Diagnostic Assay

I certify that the patient being tested and/or their legal guardian have been informed of the risks, benefits, and limitations of the testing being ordered. I have obtained informed consent, as required by my own state and/or federal laws. I assume responsibilty for returning the results of the testing to the patient and/or their legal guardian and for ensuring that my patient receives appropriate guidance to understand the implications of their test results. Further, I certify that all specimens have been collected, handled, and processed in a manner consistent with those recommended by CRSP.

The CRSP SARS-CoV-2 Real-time Reverse Transcriptase (RT)-PCR Diagnostic Assay is a real-time RT-PCR test intended for the qualitative detection of nucleic acid from the SARS-CoV-2 in nasopharyngeal and oropharyngeal swabs collected from individuals who may have contracted the virus. Testing is limited to the Clinical Research Sequencing Platform at the Broad Institute which is certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA), 42 U.S.C. §263a, to perform high complexity tests.

Negative results do not preclude SARS-CoV-2 infection and should not be used as the sole basis for patient treatment or other patient management decisions. Negative results must be combined with clinical observations, patient history, and epidemiological information.

Clinical Research Sequencing Platform, LLC
320 Charles St
Cambridge, MA 02141
genomics@broadinstitute.org

Laboratory Director: Heidi Rehm, PhD, FACMG
Commonwealth of Massachusetts Clinical Laboratory License 3306
CLIA: 22D2055652 CAP: 8707596

Information for Patients and Providers please visit:
https://covid-19-test-info.broadinstitute.org/#assay-fact-sheets

BROAD INSTITUTE | CLINICAL RESEARCH SEQUENCING PLATFORM

CRSP SARS-CoV-2 Real-time Reverse Transcriptase (RT)-PCR Diagnostic Assay

Facility code (Broad Use)
NHTI_ssu

FACILITY NAME: SunnySide Up Nursing Home

PATIENT INFORMATION
(PLEASE PRINT OR AFFIX LABEL - FILL IN ALL FIELDS)

FIRST NAME: Sally
MIDDLE NAME: F
LAST NAME: Hanke
DATE OF BIRTH (mm/dd/yyyy): 2/2/1914
SEX: M ☐ F ☑ OTHER ☐
SPECIMEN COLLECTION DATE AND TIME (mm/dd/yyyy 00 00 AM/PM): 04/12/2020 10:00 AM/PM
SWAB TUBE BARCODE LABEL

Patient Demographics (Required)

Race:
- ☐ American Indian or Alaska Native
- ☐ Black or African American
- ☑ Native Hawaiian or Pacific Islander
- ☐ Asian
- ☐ White
- ☐ Other

Ethnicity:
- ☐ Hispanic or Latino
- ☑ Non-Hispanic or Latino

REQUESTING PHYSICIAN INFORMATION AND AUTHORIZATION

REQUESTING PHYSICIAN NAME: Michael Mina and Lisa Dobberteen
PHYSICIAN PHONE NO: (518) 698 2756
REQUESTING PHYSICIAN EMAIL: MJMINA@bwh.harvard.edu
REQUESTING PHYSICIAN SECURE FAX #:
REQUESTING PHYSICIAN NPI #:

Patient is...
- Symptomatic ☐
- Asymptomatic ☑

- Staff ☐
- Resident ☑

TEST ORDERED
SARS-CoV-2 Real-time Reverse Transcriptase (RT)-PCR Diagnostic Assay

I certify that the patient being tested and/or their legal guardian have been informed of the risks, benefits, and limitations of the testing being ordered. I have obtained informed consent, as required by my own state and/or federal laws. I assume responsibilty for returning the results of the testing to the patient and/or their legal guardian and for ensuring that my patient receives appropriate guidance to understand the implications of their test results. Further, I certify that all specimens have been collected, handled, and processed in a manner consistent with those recommended by CRSP.

The CRSP SARS-CoV-2 Real-time Reverse Transcriptase (RT)-PCR Diagnostic Assay is a real-time RT-PCR test intended for the qualitative detection of nucleic acid from the SARS-CoV-2 in nasopharyngeal and oropharyngeal swabs collected from individuals who may have contracted the virus. Testing is limited to the Clinical Research Sequencing Platform at the Broad Institute which is certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA), 42 U.S.C. §263a, to perform high complexity tests.

Negative results do not preclude SARS-CoV-2 infection and should not be used as the sole basis for patient treatment or other patient management decisions. Negative results must be combined with clinical observations, patient history, and epidemiological information.

Clinical Research Sequencing Platform, LLC
320 Charles St
Cambridge, MA 02141
genomics@broadinstitute.org

Laboratory Director: Heidi Rehm, PhD, FACMG
Commonwealth of Massachusetts Clinical Laboratory License 3306
CLIA: 22D2055652 CAP: 8707596

Information for Patients and Providers please visit:
https://covid-19-test-info.broadinstitute.org/#assay-fact-sheets

BROAD INSTITUTE | CLINICAL RESEARCH SEQUENCING PLATFORM

CRSP SARS-CoV-2 Real-time Reverse Transcriptase (RT)-PCR Diagnostic Assay

Facility code (Broad Use)
NHTI_ssu

FACILITY NAME: SunnySide Up Nursing Home

PATIENT INFORMATION
(PLEASE PRINT OR AFFIX LABEL - FILL IN ALL FIELDS)

FIRST NAME: Serome
MIDDLE NAME: John
LAST NAME: Michael
DATE OF BIRTH (mm/dd/yyyy): 01/01/1900
SEX: M ☑ F ☐ OTHER ☐

SPECIMEN COLLECTION DATE AND TIME (mm/dd/yyyy 00:00 AM/PM)
04/15/2020 6:__ AM/PM

SWAB TUBE BARCODE LABEL

Patient Demographics (Required)

Race:
- ☑ American Indian or Alaska Native
- ☐ Black or African American
- ☐ Native Hawaiian or Pacific Islander
- ☐ Asian
- ☐ White
- ☐ Other

Ethnicity:
- ☐ Hispanic or Latino
- ☑ Non-Hispanic or Latino

REQUESTING PHYSICIAN INFORMATION AND AUTHORIZATION

REQUESTING PHYSICIAN NAME: Michael Mina and Lisa Dobberteen
PHYSICIAN PHONE NO.: (518) 698 2756
REQUESTING PHYSICIAN EMAIL: MJMINA@bwh.harvard.edu
REQUESTING PHYSICIAN SECURE FAX #
REQUESTING PHYSICIAN NPI #

Patient is...
- Symptomatic ☑
- Asymptomatic ☐
- Staff ☐
- Resident ☑

TEST ORDERED
SARS-CoV-2 Real-time Reverse Transcriptase (RT)-PCR Diagnostic Assay

I certify that the patient being tested and/or their legal guardian have been informed of the risks, benefits, and limitations of the testing being ordered. I have obtained informed consent, as required by my own state and/or federal laws. I assume responsibilty for returning the results of the testing to the patient and/or their legal guardian and for ensuring that my patient receives appropriate guidance to understand the implications of their test results. Further, I certify that all specimens have been collected, handled, and processed in a manner consistent with those recommended by CRSP.

The CRSP SARS-CoV-2 Real-time Reverse Transcriptase (RT)-PCR Diagnostic Assay is a real-time RT-PCR test intended for the qualitative detection of nucleic acid from the SARS-CoV-2 in nasopharyngeal and oropharyngeal swabs collected from individuals who may have contracted the virus. Testing is limited to the Clinical Research Sequencing Platform at the Broad Institute which is certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA), 42 U.S.C. §263a, to perform high complexity tests.

Negative results do not preclude SARS-CoV-2 infection and should not be used as the sole basis for patient treatment or other patient management decisions. Negative results must be combined with clinical observations, patient history, and epidemiological information.

Clinical Research Sequencing Platform, LLC
320 Charles St
Cambridge, MA 02141
genomics@broadinstitute.org

Laboratory Director: Heidi Rehm, PhD, FACMG
Commonwealth of Massachusetts Clinical Laboratory License 3306
CLIA: 22D2055652 CAP: 8707596

Information for Patients and Providers please visit:
https://covid-19-test-info.broadinstitute.org/#assay-fact-sheets